BRAF inhibition and the spectrum of granulomatous reactions
| Autor: | Kevin Phan, Anthony M. Joshua, Annika Smith, James P. Pham, Phoebe Star, Yanni Loh |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Proto-Oncogene Proteins B-raf
medicine.medical_specialty Skin Neoplasms Granuloma formation medicine.medical_treatment Dermatology Targeted therapy Mice medicine Animals Humans Vemurafenib Melanoma Protein Kinase Inhibitors neoplasms business.industry MEK inhibitor Cancer Dabrafenib medicine.disease Granuloma Mutation Sarcoidosis business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 87:605-613 |
| ISSN: | 0190-9622 |
| Popis: | BRAF-inhibitors have emerged as a promising targeted therapy for malignancies with BRAF mutations, particularly metastatic melanoma. However, granulomatous reactions including sarcoidosis and sarcoid-like-reactions have been reported as a consequence of BRAF-inhibition. It is important to adequately characterise these granulomatous reactions including cutaneous manifestations and systemic involvement, in order to guide investigations and management. A literature review was conducted to characterise the spectrum of granulomatous reactions associated with BRAF-inhibitors - identifying 55 reactions affecting 51 patients, with 37 reactions limited to cutaneous involvement. Further, possible correlation with cancer response, mechanisms of granuloma formation, as well as a proposed workup and management approach for these granulomatous reactions are presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect